ASX - By Stock
|
CHM |
Re:
Ann: Notice of Extraordinary General Meeting/Proxy Form
|
|
KrushingIt
|
198 |
45K |
7 |
27/05/24 |
27/05/24 |
ASX - By Stock
|
198
|
45K
|
7
|
|
ASX - By Stock
|
CHM |
Re:
Ann: Notice of Extraordinary General Meeting/Proxy Form
|
|
KrushingIt
|
198 |
45K |
3 |
27/05/24 |
27/05/24 |
ASX - By Stock
|
198
|
45K
|
3
|
|
ASX - By Stock
|
CHM |
Re:
Ann: CHM CDH17 Phase 1/2 clinical trial approved for initiation
|
|
KrushingIt
|
18 |
6.4K |
26 |
22/05/24 |
22/05/24 |
ASX - By Stock
|
18
|
6.4K
|
26
|
|
ASX - By Stock
|
CHM |
Re:
Ann: Resignation of CEO and Managing Director
|
|
KrushingIt
|
61 |
20K |
2 |
22/05/24 |
22/05/24 |
ASX - By Stock
|
61
|
20K
|
2
|
|
ASX - By Stock
|
CHM |
Re:
Ann: Chimeric opens CHM CDH17 Phase 1/2 trial
|
|
KrushingIt
|
14 |
3.3K |
5 |
22/05/24 |
22/05/24 |
ASX - By Stock
|
14
|
3.3K
|
5
|
|
ASX - By Stock
|
CHM |
Re:
Ann: CHM CDH17 Phase 1/2 clinical trial approved for initiation
|
|
KrushingIt
|
18 |
6.4K |
8 |
21/05/24 |
21/05/24 |
ASX - By Stock
|
18
|
6.4K
|
8
|
|
ASX - By Stock
|
CHM |
Re:
Chimeric: Media Thread
|
|
KrushingIt
|
694 |
280K |
3 |
19/05/24 |
19/05/24 |
ASX - By Stock
|
694
|
280K
|
3
|
|
ASX - By Stock
|
CHM |
Re:
Ann: CHM CORE-NK vactosertib Phase 1b study re-opens enrolment
|
|
KrushingIt
|
17 |
3.9K |
12 |
17/05/24 |
17/05/24 |
ASX - By Stock
|
17
|
3.9K
|
12
|
|
ASX - By Stock
|
CHM |
Re:
Ann: CHM CORE-NK vactosertib Phase 1b study re-opens enrolment
|
|
KrushingIt
|
17 |
3.9K |
11 |
17/05/24 |
17/05/24 |
ASX - By Stock
|
17
|
3.9K
|
11
|
|
ASX - By Stock
|
CHM |
Re:
Ann: CHM CORE-NK vactosertib Phase 1b study re-opens enrolment
|
|
KrushingIt
|
17 |
3.9K |
5 |
16/05/24 |
16/05/24 |
ASX - By Stock
|
17
|
3.9K
|
5
|
|
ASX - By Stock
|
CHM |
Re:
Ann: Notice of Extraordinary General Meeting/Proxy Form
|
|
KrushingIt
|
198 |
45K |
1 |
14/05/24 |
14/05/24 |
ASX - By Stock
|
198
|
45K
|
1
|
|
ASX - By Stock
|
CHM |
Re:
Ann: Resignation of CEO and Managing Director
|
|
KrushingIt
|
61 |
20K |
4 |
02/05/24 |
02/05/24 |
ASX - By Stock
|
61
|
20K
|
4
|
|
ASX - By Stock
|
CHM |
Re:
Ann: Resignation of CEO and Managing Director
|
|
KrushingIt
|
61 |
20K |
5 |
01/05/24 |
01/05/24 |
ASX - By Stock
|
61
|
20K
|
5
|
|
ASX - By Stock
|
CHM |
Re:
Chimeric: Media Thread
|
|
KrushingIt
|
694 |
280K |
9 |
29/04/24 |
29/04/24 |
ASX - By Stock
|
694
|
280K
|
9
|
|
ASX - By Stock
|
CHM |
Re:
Chimeric: Media Thread
|
|
KrushingIt
|
694 |
280K |
9 |
29/04/24 |
29/04/24 |
ASX - By Stock
|
694
|
280K
|
9
|
|
ASX - By Stock
|
CHM |
Re:
Chimeric: Media Thread
|
|
KrushingIt
|
694 |
280K |
16 |
26/04/24 |
26/04/24 |
ASX - By Stock
|
694
|
280K
|
16
|
|
ASX - By Stock
|
CHM |
Re:
Chimeric: Media Thread
|
|
KrushingIt
|
694 |
280K |
9 |
25/04/24 |
25/04/24 |
ASX - By Stock
|
694
|
280K
|
9
|
|
ASX - By Stock
|
CHM |
Re:
Chimeric: Media Thread
|
|
KrushingIt
|
694 |
280K |
6 |
25/04/24 |
25/04/24 |
ASX - By Stock
|
694
|
280K
|
6
|
|
ASX - By Stock
|
TVN |
Re:
Ann: Tivan Upgrades Resource Estimate - Speewah Flourite Project
|
|
KrushingIt
|
31 |
11K |
28 |
22/04/24 |
22/04/24 |
ASX - By Stock
|
31
|
11K
|
28
|
|
ASX - By Stock
|
CHM |
Re:
Chimeric: Media Thread
|
|
KrushingIt
|
694 |
280K |
7 |
22/04/24 |
22/04/24 |
ASX - By Stock
|
694
|
280K
|
7
|
|
ASX - By Stock
|
TVN |
Re:
MASDP Public Hearings in NT
|
|
KrushingIt
|
2 |
1.2K |
16 |
11/04/24 |
11/04/24 |
ASX - By Stock
|
2
|
1.2K
|
16
|
|
ASX - By Stock
|
CHM |
Re:
Ann: Change of Director's Interest Notice PH
|
|
KrushingIt
|
2 |
1.3K |
3 |
09/04/24 |
09/04/24 |
ASX - By Stock
|
2
|
1.3K
|
3
|
|